George Elston - 25 May 2025 Form 4 Insider Report for EyePoint Pharmaceuticals, Inc. (EYPT)

Role
Chief Financial Officer
Signature
/s/ Ron Honig, Attorney-in-Fact
Issuer symbol
EYPT
Transactions as of
25 May 2025
Net transactions value
-$12,507
Form type
4
Filing time
27 May 2025, 16:08:43 UTC
Previous filing
11 Feb 2025
Next filing
22 Sep 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Elston George Chief Financial Officer C/O EYEPOINT PHARMACEUTICALS, INC., 480 PLEASANT STREET, WATERTOWN /s/ Ron Honig, Attorney-in-Fact 27 May 2025 0001429932

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EYPT Common Stock Options Exercise $0 +7,500 +9.9% $0.000000 83,050 25 May 2025 Direct
transaction EYPT Common Stock Tax liability $12,507 -2,202 -2.7% $5.68 80,848 25 May 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction EYPT Restricted Stock Units Options Exercise $0 -7,500 -50% $0.000000 7,500 25 May 2025 Common Stock 7,500 $0.000000 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 No shares were sold - these shares were withheld by the issuer to satisfy tax withholding requirements in connection with the Reporting Person's exercise of his withholding right following the vesting of the restricted stock units.
F2 The restricted stock units vest in three ratable annual installments beginning May 25, 2024.